Senate Commerce Committee Statement to Senate, No. 526 — State of New Jersey (January 27, 2020)

Summary

The Senate Commerce Committee of the State of New Jersey, in a statement dated January 27, 2020, reports favorably and with committee amendments Senate Bill No. 526. The bill makes findings on the rising cost of insulin and requires health benefits plans, including the State Health Benefits Program and the School Employees' Health Benefits Program, to cover insulin for the treatment of diabetes. Insulin purchases may not be subject to any deductible, and the copayment or coinsurance for an insulin prescription is limited to $50 per 30 day supply. Insulin manufacturers must submit an annual report to the Commissioner of Banking and Insurance on manufacture, pricing and sales.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SENATE COMMERCE COMMITTEE

STATEMENT TO

SENATE, No.
526

with
committee amendments

STATE
OF NEW JERSEY

DATED: JANUARY
27, 2020

The Senate Commerce Committee reports favorably and
with committee amendments Senate Bill No. 526.

This
bill makes certain findings and declarations concerning the rising cost of
insulin and requires health benefits plans issued pursuant to the New Jersey
Individual Health Coverage and Small Employer Health Benefits Programs, the
State Health Benefits Program, and the School Employees’ Health Benefits
Program, to provide coverage for insulin for the treatment of diabetes. The
bill further requires health insurers (health, hospital and medical service
corporations, commercial individual and group health insurers, and health
maintenance organizations) and health benefits plans issued pursuant to the New
Jersey Individual Health Coverage and Small Employer Health Benefits Programs,
the State Health Benefits Program, and the School Employees’ Health Benefits
Program to provide coverage for the
purchase of insulin that is not subject to any deductible and to limit the copayment or coinsurance that may be
required for an insulin prescription to $50 per 30 day supply of insulin.

The bill also requires insulin manufacturers to submit an annual report to the Commissioner of Banking
and Insurance containing certain information concerning the manufacture,
pricing, and sales of insulin products.

This bill was pre-filed for introduction in the
2020-2021 session pending technical review. As reported, the bill includes the
changes required by technical review, which has been performed.

COMMITTEE AMENDMENTS:

The committee amended the bill to:

(1) provide that the
purchase of insulin shall not be subject to any deductible and require health
insurers to limit the copayment or coinsurance that may be required for an
insulin prescription to $50 per 30 day supply of insulin;

(2) add findings and
declarations concerning the rising cost of insulin prices;

(3) require insulin
manufacturers to submit an annual report to the Commissioner of Banking and
Insurance containing certain information concerning the manufacture, pricing,
and sales of insulin products; and

(4) make certain
technical changes.

File and source

File

2020-01-27_SCM_S526_S1.htm

Size

7,479 bytes

SHA-256

0eef1dfb6b1474c8031a25696f58c64879931368d77a96f19f333f08bc6a4c44

Our copy

2020-01-27_SCM_S526_S1.htm

Original

No public link identified.